|
Market Closed -
Euronext Paris
16:55:00 19/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.2970 EUR | -1.00% |
|
-3.88% | -0.34% |
| 09-16 | Nicox to present NCX 470 data at a conference |  |
| 09-11 | Chinese Regulator Accepts Nicox's Glaucoma Drug Application for Review | MT |
| Market Cap | 26.17M 29.35M 24.26M 22.06M 41.4M 2.79B 42.04M 291M 114M 1.45B 110M 108M 4.65B | P/E 2026 * |
-6x | P/E 2027 * | 15x |
|---|---|---|---|---|---|
| Enterprise Value | 26.17M 29.35M 24.26M 22.06M 41.4M 2.79B 42.04M 291M 114M 1.45B 110M 108M 4.65B | EV / Sales 2026 * |
8.72x | EV / Sales 2027 * | 2.62x |
| Free-Float |
99.65% | Yield 2026 * |
-
| Yield 2027 * | - |
Euronext ParisEUR
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ALCOX | Real-time | |
CBOE
| COXp | Real-time | |
|
Deutsche Boerse AG
| NXOA | Delayed | |
|
CBOE
| 0RCQ | Real-time | |
|
Börse Stuttgart
| NXOA | Delayed | |
|
Boerse Muenchen
| NXOA | Real-time |
| 1 day | -1.00% | ||
| 1 week | -3.88% | ||
| Current month | -11.08% | ||
| 1 month | -11.61% | ||
| 3 months | -19.84% | ||
| 6 months | -30.53% | ||
| Current year | -0.34% |
| 1 week | 0.29 |  | 0.31 |
| 1 month | 0.29 | | 0.35 |
| Current year | 0.29 | | 0.57 |
| 1 year | 0.28 | | 0.57 |
| 3 years | 0.14 | | 0.65 |
| 5 years | 0.14 | | 3.4 |
| 10 years | 0.14 | | 13.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
CEO | Chief Executive Officer | 55 | 27/02/2024 |
Sandrine Gestin
DFI | Director of Finance/CFO | 58 | 31/12/2014 |
Emmet Purtill
PRN | Corporate Officer/Principal | - | 31/12/2005 |
| Director | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
BRD | Director/Board Member | 55 | 07/04/2024 |
Damian Marron
CHM | Chairman | 64 | 15/07/2024 |
Marc Bozec
BRD | Director/Board Member | - | 15/07/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 29/01/22 | Free | Chief Executive Officer | 15,000 | 0.0348% | ||
| 16/02/21 | Exercice | Chief Executive Officer | 10,000 | 0.0270% | ||
| 01/02/20 | Free | Chief Executive Officer | 10,000 | 0.0300% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.00% | -3.88% | -14.04% | -18.18% | 29.74M | |
| -1.33% | +5.18% | +54.50% | +104.26% | 1,120B | |
| -0.69% | -2.93% | +31.35% | +66.17% | 616B | |
| -0.96% | +2.25% | +23.13% | +89.36% | 504B | |
| +0.24% | +6.23% | +33.98% | +52.38% | 367B | |
| -1.59% | -1.35% | +69.39% | +40.83% | 360B | |
| -0.40% | +4.28% | +19.17% | +42.51% | 288B | |
| -0.37% | +3.35% | -1.26% | +16.85% | 258B | |
| -1.75% | +2.43% | +42.21% | +49.85% | 234B | |
| -2.00% | +1.26% | +24.64% | +92.13% | 194B | |
| Average | -0.30% | +2.69% | +28.31% | +53.62% | 394.09B | |
| Weighted average by Cap. | -0.46% | +3.52% | +37.89% | +71.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3M 3.36M 2.78M 2.53M 4.74M 319M 4.82M 33.35M 13.09M 167M 12.62M 12.35M 533M | 10M 11.21M 9.27M 8.43M 15.82M 1.06B 16.06M 111M 43.64M 556M 42.07M 41.18M 1.78B |
| Net income | -5M -5.61M -4.63M -4.21M -7.91M -532M -8.03M -55.58M -21.82M -278M -21.04M -20.59M -889M | 2M 2.24M 1.85M 1.69M 3.16M 213M 3.21M 22.23M 8.73M 111M 8.41M 8.24M 356M |
| Net Debt | - | - |
Employees
10
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/10/26 | €0.2970 | -1.00% | 82,389 |
| 16/10/26 | €0.3000 | +1.69% | 89,432 |
| 15/10/26 | €0.2950 | +1.72% | 51,334 |
| 14/10/26 | €0.2900 | -3.49% | 264,337 |
| 13/10/26 | €0.3005 | -0.66% | 100,962 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2970EUR
Average target price
1.000EUR
Spread / Average Target
+236.70%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALCOX Stock
Select your edition
All financial news and data tailored to specific country editions
